Form 8-K - Current report:
SEC Accession No. 0001104659-25-089245
Filing Date
2025-09-11
Accepted
2025-09-11 07:30:54
Documents
13
Period of Report
2025-09-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2525781d1_8k.htm   iXBRL 8-K 39350
  Complete submission text file 0001104659-25-089245.txt   280372

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA abbv-20250911.xsd EX-101.SCH 4500
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abbv-20250911_def.xml EX-101.DEF 29945
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE abbv-20250911_lab.xml EX-101.LAB 40066
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abbv-20250911_pre.xml EX-101.PRE 28153
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2525781d1_8k_htm.xml XML 10622
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 251307221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)